Bicycle Reports First Patient Dosing in P-IIa Study of BT1718 for MT1-MMP-Positive Squamous NSCLC

 Bicycle Reports First Patient Dosing in P-IIa Study of BT1718 for MT1-MMP-Positive Squamous NSCLC

Bicycle Reports First Patient Dosing in P-IIa Study of BT1718 for MT1-MMP-Positive Squamous NSCLC

Shots:

  • The first patient has been dosed in the P-IIa expansion portion of P- I/IIa study, assessing BT1718 (qw) at RP2D of 20 mg/m2  in patients with MT1-MMP+ sq. NSCLC and a basket of other MT1-MMP+ solid tumors
  • The focus of the study is to evaluate the safety and tolerability profiles of BT1718 while the secondary objective is to assess the anti-tumor response. The study is sponsored by Cancer Research UK
  • BT1718 is a BTC targeting MT1-MMP and is consist of a mono-hindered disulfide cleavable linker and a cytotoxic DM1 payload

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post